Evaluation of Safety of Cabazitaxel (Jevtana) in Patients With Metastatic Hormone Refractory Prostate Cancer
Status:
Completed
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
Primary Objective:
To evaluate the safety of cabazitaxel (Jevtana) in patients with metastatic hormone
refractory prostate cancer
Secondary Objectives:
1. To describe the use of cabazitaxel (Jevtana) in combination with oral prednisolone for
the treatment of patients with metastatic Hormone Refractory Prostate Cancer
2. To describe patient profile in terms of demography, disease characteristics and prior
treatment history
3. To describe efficacy outcomes: radiological response (if available) using Recist
criteria V 1.1 and Prostate Specific Antigen (PSA) response